Locations:
SearchBrexanolone injection may bring relief from postpartum depression within three days, though some questions remain
CHANGE
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
The first ever medication indicated to treat moderate to severe postpartum depression by helping regulate the hormone levels that drop after childbirth has received FDA approval.
Designated a breakthrough therapy, FDA gave the medication, brexanolone injection, priority review. This is particularly timely as Ob/Gyns implement the new recommendations from the American College of Obstetricians and Gynecologists (ACOG) for earlier, and more frequent, postpartum care.
Sold by Sage Therapeutics, brexanolone injection is the first pharmacological therapy specifically indicated for postpartum depression. The medication works quickly—within a few days according to three company-sponsored clinical trials. Specifically, clinical trials found brexanolone injection led to clinically meaningful reductions in the Hamilton Rating Scale for Depression (HAM-D) score at 60 hours compared to the placebo.
Advertisement
Advertisement
First full characterization of kidney microbiome unlocks potential to prevent kidney stones CHANGE First full characterization of kidney microbiome unlocks potential to prevent kidney stones First full characterization of kidney microbiome unlocks potential to prevent kidney stones
First full characterization of kidney microbiome unlocks potential to prevent kidney stones change First full characterization of kidney microbiome unlocks potential to prevent kidney stones First full characterization of kidney microbiome unlocks potential to prevent kidney stones
First full characterization of kidney microbiome unlocks potential to prevent kidney stones change PUBLISH First full characterization of kidney microbiome unlocks potential to prevent kidney stones First full characterization of kidney microbiome unlocks potential to prevent kidney stones
Researchers develop first-of-its-kind neoantigen atlas to better understand immunotherapy resistance
Lorem ipsum dolor sit amet. Ea dolor obcaecati et rerum odio est totam incidunt et similique corporis id impedit quis est quia suscipit eos commodi molestias. Aut minus magnam HEENA ADDED THS CHANGE
Lorem ipsum dolor sit amet. Qui magni quaerat qui porro blanditiis cum voluptas ipsa! Et eveniet voluptatem ab voluptas dicta non quibusdam rerum et doloremque sequi aut earum aperiam. Ea eligendi voluptas id error eaque et deleniti quam ex voluptatem minima eum impedit consequuntur sit architecto dicta?
Lorem ipsum dolor sit amet. Qui corporis cupiditate qui harum accusantium nam saepe recusandae est voluptatum dolor ab eveniet omnis